Lookup NU author(s): Dr Henrique De Paula Lemos
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
This study was designed to test the efficacy of eugenol, a compound obtained from the essential oil of cloves (Syzygium aromaticum) in collagen-induced arthritis (CIA), a well characterized murine model of rheumatoid arthritis. Macroscopic clinical evidence of CIA manifests first as periarticular erythema and edema in the hind paws. Treatment with eugenol starting at the onset of arthritis (day 25) ameliorated these clinical signs of CIA. Furthermore, eugenol inhibited mononuclear cell infiltration into the knee joints of arthritic mice and also lowered the levels of cytokines (tumor necrosis factor (TNF)-α, interferon (IFN)-γ and tumor growth factor (TGF)-β) within the ankle joints. Eugenol treatment did not affect the in vitro cell viability as assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Therefore, eugenol ameliorates experimental arthritis and could be useful as a beneficial supplement in treating human arthritis.
Author(s): Grespan R, Paludo M, Lemos HdeP, Barbosa CP, Bersani-Amado CA, Dalalio MM, Cuman RK
Publication type: Article
Publication status: Published
Journal: Biological and Pharmaceutical Bulletins
ISSN (print): 0918-6158
ISSN (electronic): 1347-5215
Publisher: Pharmaceutical Society of Japan
PubMed id: 23037170
Altmetrics provided by Altmetric